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An abbreviated tract of five thymidines (5T) in intron 8 of the cystic fibrosis transmembrane conductance regulator
(CFTR) gene is found in ∼10% of individuals in the general population. When found in trans with a severe CFTR
mutation, 5T can result in male infertility, nonclassic cystic fibrosis, or a normal phenotype. To test whether the
number of TG repeats adjacent to 5T influences disease penetrance, we determined TG repeat number in 98 patients
with male infertility due to congenital absence of the vas deferens, 9 patients with nonclassic CF, and 27 unaffected
individuals (fertile men). Each of the individuals in this study had a severe CFTR mutation on one CFTR gene and
5T on the other. Of the unaffected individuals, 78% (21 of 27) had 5T adjacent to 11 TG repeats, compared with
9% (10 of 107) of affected individuals. Conversely, 91% (97 of 107) of affected individuals had 12 or 13 TG
repeats, versus only 22% (6 of 27) of unaffected individuals ( ). Those individuals with 5T adjacent toP ! .00001
either 12 or 13 TG repeats were substantially more likely to exhibit an abnormal phenotype than those with 5T
adjacent to 11 TG repeats (odds ratio 34.0, 95% CI 11.1–103.7, ). Thus, determination of TG repeatP ! .00001
number will allow for more accurate prediction of benign versus pathogenic 5T alleles.
Genes that are responsible for inherited disorders can
have mutations that cause disease phenotypes in some
but not all individuals. These incompletely penetrant
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mutations become problematic if they are incorporated
into clinical testing prior to an understanding of the
factors affecting penetrance. One variant that presents
a problem in the interpretation of genetic testing of the
cystic fibrosis transmembrane conductance regulator
(CFTR) gene is an abbreviated tract of five thymidines
(5T) in intron 8 (Noone et al. 2000; Strom et al. 2002).
Some individuals bearing 5T in trans with a severe cystic
fibrosis–causing mutation may have nonclassic cystic fi-
brosis (CF [MIM 219700]); others may have male in-
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fertility due to congenital bilateral absence of the vas
deferens (CBAVD [MIM 277180]); and ∼40% may be
healthy and fertile as a consequence of incomplete pen-
etrance (Chillo´n et al. 1995; Zielenski et al. 1995). Thus,
5T frequently creates an interpretative challenge for cli-
nicians due to the commonness of the variant (found in
1 in 10 individuals) and the large number of CFTR ge-
netic tests performed each year.
The 5T variant is a stretch of five contiguous thy-
midines at the 3′ end of intron 8 that exacerbates skip-
ping of exon 9, thereby resulting in reduced levels of
functional CFTR protein (Chu et al. 1993). Prior studies
have demonstrated that the number of TG repeats im-
mediately adjacent to 5T correlates with exon 9 skipping
(Cuppens et al. 1998; Niksic et al. 1999). Cuppens et
al. (1998) have also suggested that increased exon 9
skipping from transcripts bearing more TG repeats in-
creases the penetrance of 5T. However, an adequate cal-
culation of the effect of TG repeat number on 5T pen-
etrance has been hampered by small sample sizes. The
aim of this collaborative study was to evaluate whether
TG repeat number significantly aids in prediction of be-
nign versus pathogenic 5T alleles, thereby warranting its
use in clinical situations.
Identifying information was removed from all DNA
samples prior to submission to this study. The relative
frequencies of 5T and TG-T combinations were esti-
mated by screening 1,269 DNA samples from the general
populations of five countries (United States, Czech Re-
public, Poland, Italy, and Germany). To assess the effect
of TG repeat variation on penetrance of 5T, we analyzed
DNA samples from 27 unaffected fertile men, 98 pa-
tients with CBAVD, and 9 patients with nonclassic CF.
Each of the 134 individuals in this study had a severe
CF mutation on one CFTR gene and 5T on the other.
Either the 5T variant was confirmed—by studying allele
transmission in the family—to be in trans with a severe
CF mutation, or it was assumed to be in trans if the
severe CF mutation was a common mutation previously
shown not to be in linkage disequilibrium with 5T. To
identify unaffected individuals with this genotype, we
screened for 5T in 1,685 men who fathered at least one
child with classic CF (fertile, obligate carriers). Since
198% of men with CF are infertile, it is unlikely that
fathers of patients with CF have an unrecognized form
of the disease, making them an appropriate control pop-
ulation for this study. Each of the 27 fathers with 5T
had one of the following mutations: DF508 (18), G542X
(2), 1812-1GrA (2), DI507 (1), 936delTA (1), N1303K
(1), 36002insT (1), or 1717-1 GrA (1). 5T was in-
ferred to be in trans with DF508 and DI507, since these
mutations have never been shown to be in linkage dis-
equilibrium with 5T. The 5T variant was confirmed by
use of pedigree analysis to be in trans with the other
mutations. Samples from fathers of patients with CF
were referred from CF care centers from the following
countries (number of samples screened and number with
the CF mutation/5T genotype in parentheses): Czech Re-
public (202, 5), Denmark (172, 2), France (109, 2), Ger-
many (114, 1) , Greece (210, 1), Hungary (30, 2), Italy
(230, 2), Poland (100, 5), Slovakia (46, 0), Spain (384,
5), and the United States (88, 2).
Patients with CBAVD were diagnosed by palpation,
analysis of sperm, and/or rectal ultrasound. Each of the
98 patients with CBAVD had 5T with one of the fol-
lowing mutations: DF508 (78), G542X (6), N1303K (3),
7111GrT (2), R1066C (2), R1162X (2), R764X (1),
Y563X (1), H609R (1), L206W (1), or R334W (1). 5T
was confirmed by use of pedigree analysis to be in trans
with R764X, Y563X, and H609X and was inferred as
in trans for the remaining mutations, since these mu-
tations have never been found to be in linkage disequi-
librium with 5T in previous population sampling. Pa-
tients with CBAVD were referred from the following
countries (number with the CF mutation/5T genotype):
Denmark (6), France (35), Germany (8), Greece (1), Italy
(4), Poland (6), Spain (29), the United Kingdom (6), and
the United States (3).
Nine patients with nonclassic CF were referred from
CF care centers in the United States and were confirmed
to have a 5T in trans with one of the following CFTR
mutations: DF508 (6), 2814insA (1), G463D (1), or
F693L (1). For each patient, we scanned the entire cod-
ing region of the CFTR gene to rule out the presence of
rare mutations in addition to 5T (DNA sequencing
, denaturating gradient gel electrophoresisnp 6
[DGGE] ). Each patient met current diagnosticnp 3
criteria for CF by demonstrating both CFTR dysfunc-
tion, and at least one clinical feature of CF (Rosenstein
and Cutting 1998). Specifically, six of the nine patients
had respiratory disease consistent with CF, as well as
CFTR dysfunction, as indicated by elevated mean sweat
Cl concentration (58–70 mmol/L). Of the remaining
three patients, each had evidence of CFTR dysfunction,
as indicated by borderline sweat Cl concentration (43–
49 mmol/L), and abnormally reduced low Cl buffer/
isoproterenol response, as demonstrated by the nasal
potential difference (NPD) test. Of these three patients,
one had mild respiratory disease, one had elevated serum
trypsinogen in the newborn period, and one had elevated
quantitative fecal fat levels consistent with pancreatic
insufficiency.
To detect samples positive for 5T, PCR products were
fixed on Hybond N nylon membranes (Amersham Bi-
osciences) and were probed with the 32P end-labeled
probe 5′-TGTGTGTGTTTTTAACAG. Samples that
were positive for 5T were sequenced bidirectionally and
analyzed by automated capillary electrophoresis (Ap-
plied Biosystems) to determine TG repeat number and
phase of TG-T repeat combinations. Samples from
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Table 1
Frequency of the 5T Allele and TG-5T Combinations in the General Population
COUNTRY
OF ORIGIN
DNA
SAMPLES
SCREENED
5T ALLELE
FREQUENCY
5T COMBINATIONS
(PROPORTION OF 5T ALLELES)
TG11-5T TG12-5T TG13-5T
United States 517 0.048 36 (0.72) 13 (0.26) 1 (0.02)
Czech Republic 251 0.030 14 (0.93) 1 (0.07) 0 (0.00)
Poland 132 0.053 13 (0.93) 1 (0.07) 0 (0.00)
Italy 173 0.038 9 (0.70) 4 (0.30) 0 (0.00)
Germany 196 0.041 11 (0.69) 4 (0.25) 1 (0.06)
Total 1269 0.043 83 (0.77) 23 (0.21) 2 (0.02)
Table 2
Distribution of the TG-5T Combinations in Unaffected and Affected Individuals, by Country
of Origin
COUNTRY
OF ORIGIN
NO. OF OCCURRENCES IN
Unaffected Individuals Affected Individuals
TG11-5T TG12-5T TG13-5T TG11-5T TG12-5T TG13-5T
France 2 … … 2 28 5
Spain 4 1 … 4 25 …
United States 1 1 … … 8 4
Poland 5 … … 1 4 1
Germany … 1 … 1 4 3
Denmark 2 … … 2 2 2
Italy 2 … … … 4 …
United Kingdom … … … … 5 1
Czech Republic 3 2 … … … …
Greece 1 … … … 1 …
Hungary 1 1 … … … …
France, Italy, Greece, and Spain were screened using
DGGE or restriction enzyme digestion.
Allele frequencies for 5T were similar among the five
general population groups and were consistent with pre-
vious reports (table 1). 5T was found in cis with three
different TG repeats (TG11-5T, TG12-5T, TG13-5T).
Although variation in the frequencies of these combi-
nations was observed among populations, TG11-5T was
by far the most common in all five populations, followed
by TG12-5T and TG13-5T (table 1).
TG12-5T and TG13-5T were more frequent in the
affected patients than controls across each of the pop-
ulations sampled (table 2), and the frequencies of the
different TG-T combinations differed significantly be-
tween the unaffected and affected groups (table 3). The
most frequent combination, TG11-5T, was found in
78% of unaffected individuals, versus 9% of affected
individuals (table 3), suggesting that TG11-5T is gen-
erally benign. TG12-5T was the most common disease-
associated combination, and was found in 76% of af-
fected individuals versus 22% of unaffected individuals.
It is interesting to note that TG13-5T was found exclu-
sively in affected individuals (table 3). These findings
demonstrate that, when 5T is found in trans with a se-
vere CF mutation, the odds of pathogenicity are 28 and
34 times greater for TG12-5T and TG13-5T, respec-
tively, than for TG11-5T (table 3).
Previous studies have suggested that another common
variant in CFTR, a methionine or valine at codon 470,
also influences the penetrance of 5T (Cuppens et al.
1998; de Meeus et al. 1998). To test whether this variant
affects the penetrance of 5T, we established phase be-
tween TG-T combinations and this variant in 22 unaf-
fected and 92 affected individuals. As reported else-
where, TG11-5T was always found with M470, and, in
all but five cases, TG12-5T was found with V470 (data
not shown). The highly penetrant TG13-5T was found
to occur only with M470 in all of the cases in which
phase could be established ( ). The correlationnp 15
between increased penetrance and TG repeat number,
lack of correlation with variation at codon 470, and
experimental evidence of increased exon 9 skipping with
more TG repeats indicates that TG repeat number, rather
than M470V status, is the major determinant of pene-
trance for 5T.
Our analysis demonstrates that knowledge of TG re-
peat number in individuals with 5T is of diagnostic
value. When TG repeat number is determined, the sen-
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Table 3
Frequency of the TG-5T Combinations in Unaffected and Affected
Individuals with a CF Mutation/5T Genotype
STATUS
NO. OF INDIVIDUALS
All Samples TG11-5T TG12-5Ta TG13-5Tb
Unaffected:
Fertile men 27 21 6 0
Affected:
CBAVD 98 10 76 12
Nonclassic CF 9 0 5 4
Total affected 107 10 81 16
NOTE.—Odds ratios were calculated by comparing the frequency
of the TG12-T5 or TG13-T5 combination to the frequency of the
putatively benign TG11-T5 combination in affected versus unaffected
individuals.
a Odds ratio 28.4, 95% CI 9.3–86.9, .P ! .00001
b Odds ratio 34.0, 95% CI 4.0–289.8, .P ! .0001
sitivity for identifying affected individuals is 91%,
whereas the specificity for identifying those who are un-
affected is 78%. After adjusting for differences in sample
sizes of the affected and unaffected groups, we used the
proportion of each TG-T combination in affected in-
dividuals to estimate that the disease risk for males with
TG11-5T is 0.10, TG12-5T is 0.78, and TG13-5T is
1.0. Since CBAVD accounts for a large component of
the disease risk in this study, the risk of pathogenicity
will likely be lower for females. Nonetheless, a female
carrying TG12-5T or TG13-5T in trans with a CF mu-
tation will be at higher risk of developing nonclassic CF
than if she carried the TG11-5T allele.
The association between TG repeat number and dis-
ease penetrance demonstrated in this study is consistent
with molecular studies correlating TG repeat number
with aberrant CFTR splicing (Cuppens et al. 1998; Nik-
sic et al. 1999; Hefferon et al., in press) and validates
clinical use of TG repeat testing in counseling individuals
with 5T. This information will have important clinical
relevance, since ∼25 million individuals in the United
States are predicted to carry at least one 5T allele. Al-
though TG repeat number proves to be a reliable pre-
dictor of penetrance for 5T, further studies are required
to elucidate the factors that determine whether an in-
dividual will develop multisymptomatic (nonclassic CF)
or monosymptomatic (CBAVD) disease.
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